A retrospective study identifying predictive factors for therapeutic response, including programmed death-ligand 1 (PD-L1) expression in tumors, for docetaxel treatment in combination with ramucirumab
Latest Information Update: 08 Jul 2020
Price :
$35 *
At a glance
- Drugs Docetaxel (Primary) ; Ramucirumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 08 Jul 2020 New trial record
- 24 Jun 2020 Results presented at the 111th Annual Meeting of the American Association for Cancer Research - II